In a 60-year-old woman with follicular lymphoma, 14 days post‑autologous stem‑cell transplant, who now has fever, tachycardia, tachypnea, normotension, bilateral crackles, bilateral alveolar infiltrates, a diffuse maculopapular rash, mild diarrhea, anemia, leukopenia, thrombocytopenia, normal renal function, and a PaO₂/FiO₂ ratio of approximately 156 on FiO₂ 0.5, what is the best next step: serum galactomannan assay, echocardiogram, colonoscopy, or bronchoscopy?

Bronchoscopy is the best next step

In this patient with fever, bilateral pulmonary infiltrates, rash, and diarrhea at day 14 post-autologous stem cell transplant, bronchoscopy with bronchoalveolar lavage should be performed immediately to establish a definitive diagnosis and guide targeted therapy.

Clinical Reasoning

This patient presents during Phase II (postengraftment, days 30-100) of stem cell transplant recovery, though at the early end (day 14). The guideline framework indicates that during this phase, impaired cell-mediated immunity dominates, with CMV, Pneumocystis carinii, and Aspergillus species being the critical pathogens 1. However, the clinical triad of fever, diffuse maculopapular rash, diarrhea, and bilateral pulmonary infiltrates occurring around neutrophil engraftment also raises concern for engraftment syndrome.

Why Bronchoscopy is Essential

The bilateral alveolar infiltrates with severe hypoxemia (PaO₂/FiO₂ ratio ~156, indicating moderate ARDS) require immediate diagnostic clarification because:

• Multiple life-threatening etiologies must be distinguished: opportunistic infections (CMV pneumonitis, Pneumocystis, invasive fungal infection) versus engraftment syndrome
• Treatment differs dramatically: antimicrobials for infection versus corticosteroids for engraftment syndrome
• Mortality risk is substantial: untreated CMV pneumonitis or invasive aspergillosis carries high mortality, while engraftment syndrome with periengraftment respiratory distress syndrome (PERDS) has mortality up to 21% 2, 3

Bronchoscopy with BAL allows:

• Direct visualization and sampling of lower airways
• Microbiologic studies (bacterial/fungal cultures, viral PCR including CMV, Pneumocystis staining)
• Galactomannan testing on BAL fluid (80% sensitivity for Aspergillus, superior to serum) 4
• Cytologic examination to exclude alveolar hemorrhage or other processes

Why Other Options Are Inadequate

Serum galactomannan assay alone has limited utility here:

• Sensitivity only 58-65% in hematologic malignancy patients 4
• False positives with piperacillin-tazobactam (already started) 4
• Does not detect CMV, Pneumocystis, or bacterial pathogens
• Single negative result cannot rule out invasive fungal infection 4

Echocardiogram would not address the primary diagnostic dilemma of infection versus engraftment syndrome, though cardiogenic pulmonary edema is already excluded by the clinical picture.

Colonoscopy is premature—the mild diarrhea could be explained by CMV colitis, GVHD (though rare in autologous transplant 5), or engraftment syndrome, but the life-threatening pulmonary process takes diagnostic priority.

Diagnostic Approach

1. Perform bronchoscopy urgently with BAL from multiple lobes

2. Send BAL for:

   • Bacterial, fungal, mycobacterial cultures
   • CMV PCR/culture (critical pathogen in this phase 1)
   • Pneumocystis jirovecii staining
   • Galactomannan (superior to serum in BAL fluid 4)
   • β-D-glucan if available
   • Cytology

3. Maintain broad empiric coverage with piperacillin-tazobactam while awaiting results

4. Consider empiric antifungal therapy if bronchoscopy is delayed or clinical deterioration occurs, using agents with mold coverage (voriconazole, isavuconazole, or liposomal amphotericin B) 4

5. Evaluate for engraftment syndrome using Maiolino criteria 2:

   • Fever without documented infection
   • Erythematous skin rash
   • Noncardiogenic pulmonary infiltrates
   • Occurring around neutrophil recovery
   • If confirmed and infection excluded, initiate corticosteroids (typically methylprednisolone 1-2 mg/kg/day) 3

Critical Pitfalls to Avoid

• Do not delay bronchoscopy for non-invasive testing—the diagnostic yield and therapeutic implications are too important
• Do not assume engraftment syndrome without excluding infection, as corticosteroids would be catastrophic if CMV pneumonitis or invasive fungal infection is present
• Do not rely on serum galactomannan alone given its poor sensitivity and confounding by piperacillin-tazobactam 4
• Do not wait for neutrophil count recovery to act—this patient is already intubated with severe respiratory failure requiring immediate diagnosis

The combination of severe hypoxemic respiratory failure, bilateral infiltrates, and immunocompromised status in the postengraftment phase mandates direct sampling of the lower respiratory tract to guide life-saving therapy 1.